DelveInsight’s, “Cutaneous Lupus Erythematosus (CLE) – Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cutaneous Lupus Erythematosus (CLE) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Cutaneous Lupus Erythematosus (CLE): Overview
Lupus erythematosus (LE) is a connective tissue disease and autoimmune disorder that can affect one or several organs. Circulating autoantibodies and immune complexes are due to loss of normal immune tolerance and are pathogenic. The clinical features of LE are highly variable. LE nearly always affects the skin to some degree. Cutaneous LE comprises several chronic and relapsing LE-specific and LE-nonspecific inflammatory conditions. There can be some overlap:
Diagnosis
A skin biopsy may be diagnostic, showing a lichenoid tissue reaction and features specific to the kind of cutaneous LE. Direct immunofluorescence tests may show positive antibody deposition along the basement membrane (lupus band test).
Treatment
Treatment may vary depending upon type of Cutaneous Lupus Erythematosus (CLE): The aim of treatment for cutaneous LE is to prevent flares, improve appearance and to prevent scarring.
Local therapy
Systemic therapy
Treatment for cutaneous and systemic LE may include:
This segment of the Cutaneous Lupus Erythematosus (CLE) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cutaneous Lupus Erythematosus (CLE) Emerging Drugs
Filgotinib: Galapagos/Gilead Sciences
Filgotinib (GLPG0634/GS-6034) is a potent and selective inhibitor of JAK1,7 which is currently under investigation for the treatment Cutaneous Lupus Erythematosus (CLE). It is currently in phase II stage of development.
VIB7734: Viela Bio.
VIB7734 potentially represents a novel treatment for autoimmune diseases caused by the overproduction of type I interferons and other cytokines secreted by a type of dendritic cell called pDCs. VIB7734 is designed to target and bind to ILT7, a cell surface molecule specific to pDCs, leading to their depletion. The benefits are multifold as this depletion may also decrease other inflammatory cytokines such as TNF-a and IL-6, which are critical to the pathogenesis of a number of autoimmune diseases. Viela Bio have completed a phase Ia single-ascending dose trial in patients with various autoimmune diseases including Cutaneous Lupus Erythematosus (CLE) (CLE).
HT-005 Z-Pods: Hoth Therapeutics/Zylo Therapeutics
Hoth has entered a partnership agreement with Zylö Therapeutics Inc to co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosus (CLE) (CLE). HT-005 Z-Pods includes a novel topical delivery matrix (Z-Pods) loaded with an endogenous ligand with suspected immune-modulating action. Z-Pods use patented xerogel-derived nanoparticles for sustained and controlled topical delivery of active pharmaceutical ingredients. The HT-005 Z-Pods™ product is currently in the early preclinical stage of development.
Further product details are provided in the report……..
This segment of the report provides insights about the different Cutaneous Lupus Erythematosus (CLE) drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 15+ key companies which are developing the therapies for Cutaneous Lupus Erythematosus (CLE). The companies which have their Cutaneous Lupus Erythematosus (CLE) drug candidates in the most advanced stage, i.e. phase II include Galapagos/Gilead Sciences and others
DelveInsight’s report covers around 15+ products under different phases of clinical development like
Cutaneous Lupus Erythematosus (CLE) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cutaneous Lupus Erythematosus (CLE) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cutaneous Lupus Erythematosus (CLE) drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Cutaneous Lupus Erythematosus (CLE): Overview
Pipeline Therapeutics
Therapeutic Assessment
Cutaneous Lupus Erythematosus (CLE) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Cutaneous Lupus Erythematosus (CLE) Collaboration Deals
Late Stage Products (Phase III)
Drug Name: Company Name
Mid Stage Products (Phase II)
Filgotinib: Galapagos/Gilead Sciences
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
VIB7734: Viela Bio.
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
HT-005 Z-Pods: Hoth Therapeutics/Zylo Therapeutics
Inactive Products
Cutaneous Lupus Erythematosus (CLE) Key Companies
Cutaneous Lupus Erythematosus (CLE) Key Products
Cutaneous Lupus Erythematosus (CLE)- Unmet Needs
Cutaneous Lupus Erythematosus (CLE)- Market Drivers and Barriers
Cutaneous Lupus Erythematosus (CLE)- Future Perspectives and Conclusion
Cutaneous Lupus Erythematosus (CLE) Analyst Views
Cutaneous Lupus Erythematosus (CLE) Key Companies
Appendix
List of Table
Table 1: Total Products for Cutaneous Lupus Erythematosus (CLE)
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Cutaneous Lupus Erythematosus (CLE)
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Hoth Therapeutics
• Zylo Therapeutics
• Galapagos
• Gilead Sciences
• Viela Bio
• Biogen Idec
• Rigel Pharmaceuticals
• Amgen/AstraZeneca
